ESTRELLA IMMUNOPHARMA INC ESLA 深 沪
已收盘 08-01 16:00:00 美东时间
0.8549
+0.015
+1.77%
华盛通- 最 高0.87
- 今 开0.849
- 成交量 1.09万股
- 最 低 0.83
- 昨 收 0.84
- 总市值 3091.80万
- 52周最高 1.78
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 0.63
- 委 比 20.00%
- 总股本 3616.56万
- 历史最高 33.00
- 量 比 0.79
- 振 幅 4.76%
- 历史最低 0.00
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Estrella Immunopharma Announces Activation Of Second Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103 In Relapsed Or Refractory B-Cell NHL Patients
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune
06-05 20:05
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial
Estrella Immunopharma ( ($ESLA) ) just unveiled an announcement. On May 29, 202...
05-29 23:28
Estrella Immunopharma Announces First Patient Dosed In Second Cohort Of Dose Escalation Study Of Phase I/II STARLIGHT-1 Trial For EB103 To Treat Patients With Advanced B-Cell NHL
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune
05-29 20:05
美股大行评级 | 潜在涨幅75%！Solar Edge获高盛升目标价至31美元，维持买入评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1099980218194210816.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：维持Chemomab Therapeutics(CMMB)"买入"评级，目标价从4美元升至7美元</p> <p>• Citizens Capital Markets：维持德纳维制药(DVAX)"跑赢
02-24 11:50
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.
02-22 00:48
美股大行评级 | 潜在涨幅348%！万达生物制药获机构升目标价至20美元，维持“买入”评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1098890886600560640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Stoke Therapeutics(STOK)"买入"评级，目标价从35美元升至47美元</p> <p>• HC Wainwright & Co.：维持万达生物
02-19 10:24
Estrella Immunopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
- SEC Filing
2024-12-17 05:03
Estrella Immunopharma files for $100M common stock, warrants offering
Estrella Immunopharma (NASDAQ:ESLA) filed for $100M common stock, warrants offering. This prospectus is not an offer to sell. Filing More on Estrella Immunopharma, Inc. Financial information for Estre...
2024-12-13 06:19
大消费高潮
（公众号设为：“星标”，可第1时间收到文章，以免错过更新） 高度：一鸣食品12板断了。 但是下面的消费板块继续牛。整个板块丝毫不受到高位龙头震荡的影响。 ...
2024-12-12 20:30
